277 related articles for article (PubMed ID: 23695449)
41. Potential directions for drug development against galectin-7 in cancer.
St-Pierre Y; Biron-Pain K; Campion C; Lavoie G; Bouchard F; Couillard J
Expert Opin Drug Discov; 2009 Jun; 4(6):611-20. PubMed ID: 23489154
[TBL] [Abstract][Full Text] [Related]
42. Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer.
Moiseeva EV; Rapoport EM; Bovin NV; Miroshnikov AI; Chaadaeva AV; Krasilshschikova MS; Bojenko VK; Bijleveld C; van Dijk JE; Den Otter W
Breast Cancer Res Treat; 2005 Jun; 91(3):227-41. PubMed ID: 15952056
[TBL] [Abstract][Full Text] [Related]
43. Fine-tuning antitumor responses through the control of galectin-glycan interactions: an overview.
Salatino M; Rabinovich GA
Methods Mol Biol; 2011; 677():355-74. PubMed ID: 20941621
[TBL] [Abstract][Full Text] [Related]
44. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting.
Nagy N; Legendre H; Engels O; André S; Kaltner H; Wasano K; Zick Y; Pector JC; Decaestecker C; Gabius HJ; Salmon I; Kiss R
Cancer; 2003 Apr; 97(8):1849-58. PubMed ID: 12673710
[TBL] [Abstract][Full Text] [Related]
45. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
46. Galectins as modulators of tumour progression.
Liu FT; Rabinovich GA
Nat Rev Cancer; 2005 Jan; 5(1):29-41. PubMed ID: 15630413
[TBL] [Abstract][Full Text] [Related]
47. Regulatory roles of galectins in the immune response.
Liu FT
Int Arch Allergy Immunol; 2005 Apr; 136(4):385-400. PubMed ID: 15775687
[TBL] [Abstract][Full Text] [Related]
48. Roles of galectins in inflammatory bowel disease.
Hokama A; Mizoguchi E; Mizoguchi A
World J Gastroenterol; 2008 Sep; 14(33):5133-7. PubMed ID: 18777589
[TBL] [Abstract][Full Text] [Related]
49. Dissecting the signal transduction pathways triggered by galectin-glycan interactions in physiological and pathological settings.
Laderach DJ; Compagno D; Toscano MA; Croci DO; Dergan-Dylon S; Salatino M; Rabinovich GA
IUBMB Life; 2010 Jan; 62(1):1-13. PubMed ID: 20014236
[TBL] [Abstract][Full Text] [Related]
50. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
[TBL] [Abstract][Full Text] [Related]
51. Galectin Family Members: Emerging Novel Targets for Lymphoma Therapy?
Shi Y; Tang D; Li X; Xie X; Ye Y; Wang L
Front Oncol; 2022; 12():889034. PubMed ID: 35677161
[TBL] [Abstract][Full Text] [Related]
52. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis.
Rabinovich GA; Cumashi A; Bianco GA; Ciavardelli D; Iurisci I; D'Egidio M; Piccolo E; Tinari N; Nifantiev N; Iacobelli S
Glycobiology; 2006 Mar; 16(3):210-20. PubMed ID: 16282605
[TBL] [Abstract][Full Text] [Related]
53. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
[TBL] [Abstract][Full Text] [Related]
54. Galectins in the Tumor Microenvironment: Focus on Galectin-1.
Martínez-Bosch N; Navarro P
Adv Exp Med Biol; 2020; 1259():17-38. PubMed ID: 32578169
[TBL] [Abstract][Full Text] [Related]
55. Characterization of galectin-9-induced death of Jurkat T cells.
Lu LH; Nakagawa R; Kashio Y; Ito A; Shoji H; Nishi N; Hirashima M; Yamauchi A; Nakamura T
J Biochem; 2007 Feb; 141(2):157-72. PubMed ID: 17167046
[TBL] [Abstract][Full Text] [Related]
56. Reprogramming the tumor metastasis cascade by targeting galectin-driven networks.
Perrotta RM; Bach CA; Salatino M; Rabinovich GA
Biochem J; 2021 Feb; 478(3):597-617. PubMed ID: 33600595
[TBL] [Abstract][Full Text] [Related]
57. Galectin-9 in cancer therapy.
Fujihara S; Mori H; Kobara H; Rafiq K; Niki T; Hirashima M; Masaki T
Recent Pat Endocr Metab Immune Drug Discov; 2013 May; 7(2):130-7. PubMed ID: 23514536
[TBL] [Abstract][Full Text] [Related]
58. [Galectines as prognostic factors for the malignant lymphoproliferative diseases].
Sivkovych SO; Kysel'ova OA; Mel'nyk UI; Zubryts'ka TB; Serbin IM
Lik Sprava; 2012; (3-4):19-25. PubMed ID: 23356132
[TBL] [Abstract][Full Text] [Related]
59. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?
Mirandola L; Nguyen DD; Rahman RL; Grizzi F; Yuefei Y; Figueroa JA; Jenkins MR; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2014 Oct; 33(5):417-27. PubMed ID: 24801755
[TBL] [Abstract][Full Text] [Related]
60. Role of Galectins in Allergic Disorders.
Kucuksezer UC; Ozdemir C
Recent Pat Inflamm Allergy Drug Discov; 2016; 10(1):2-12. PubMed ID: 27112441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
